Endovascular Treatment and Outcomes for Femoropopliteal In-Stent Restenosis: Insights from the XLPAD Registry

Authors

Michael H Vu
Glaiza-Mae Sande-Docor
Yulun Liu
Shirling Tsai
Mitul Patel
Chris Metzger
Mehdi H Shishehbor
Emmanouil S Brilakis
Nicolas W Shammas
Peter Monteleone
Subhash Banerjee

Publication Date

1-1-2022

Journal

Journal of Interventional Cardiology

Abstract

BACKGROUND: There is limited "real-world" evidence examining treatment modalities and outcomes in patients with symptomatic peripheral arterial disease undergoing endovascular treatment of femoropopliteal (FP) in-stent restenosis (ISR).

MATERIALS AND METHODS: We compared outcomes in 2,895 patients from the XLPAD registry (NCT01904851) between 2006 and 2019 treated for FP ISR (

RESULTS: ISR patients were more frequently on antiplatelet (94.5% vs 89.4%,

CONCLUSION: Atherectomy and DCB are more frequently used to treat FP ISR lesions. Patients with FP ISR have more intraprocedural distal embolization, higher repeat revascularization procedures, and lower freedom from MALE at 1 year.

Keywords

Angioplasty, Balloon, Clinical Studies as Topic, Coated Materials, Biocompatible, Constriction, Pathologic, Coronary Restenosis, Femoral Artery, Humans, Peripheral Arterial Disease, Popliteal Artery, Registries, Treatment Outcome, Vascular Patency